American College of Gastroenterology

Fass reviews findings from a post hoc analysis of a phase 2 trial suggesting the value of vonoprazan as an on-demand NERD treatment.

Njei points to the need for improved lean MASLD screening, citing findings from his research about its prevalence and the burden of undiagnosed disease.

New ACG 2024 data show patients with both IBD and vitamin D deficiency face longer, more expensive hospital stays, as well as risk of colectomy.

Ritter reviews findings from 2 real-world studies supporting the safety and efficacy of live-jslm (Rebyota) for recurrent C Diff infection.

New late-breaking ACG 2024 data supports AIMS65 as a risk factor tool for patients undergoing anticoagulant reversal.

The CRAC channel inhibitor zegocractin significantly improved acute pancreatitis patients' time to eating food and risk of respiratory failure in new data.

Post hoc analyses from the LIBERTY trials support infliximab as either a monotherapy or combination therapy for ulcerative colitis or Crohn's disease.

Lacy explains limitations to current motility measurements and reviews findings from his study exploring the potential of a wireless motility patch system.

Test your knowledge of the 2024 American College of Gastroenterology alcohol-associated liver disease guidelines with this clinical quiz!

Test your knowledge of the 2024 American College of Gastroenterology acute pancreatitis diagnosis and management guidelines with this clinical quiz!

Test your knowledge of the 2024 American College of Gastroenterology focal liver lesion diagnosis and management guidelines with this clinical quiz!

Test your knowledge of the 2024 American College of Gastroenterology H. pylori management guidelines with this clinical quiz!

Results from both phase 2 trials were presented in poster abstracts at ACG 2023.

Kremer discusses new ad hoc findings from the phase 3 ENHANCE trial showing seladelpar's unique effect on pruritus in patients with PBC.

Findings were presented in an abstract at ACG 2023, highlighting the importance of addressing bowel urgency in patients with ulcerative colitis.

New data from ACG 2023 shows etrasimod-treated patients were able to achieve UC remission, with or without concomitant steroid treatment at baseline.

Results showed higher-exposure dupilumab met the study’s primary endpoint for peak esophageal intraepithelial count ≤6 eos/high-power field.

New QUASAR analysis shows patients with intolerance or failed response to advanced therapies nonetheless achieved benefit with guselkumab.

Results presented in a paper at ACG 2023 showed upadacitinib was more effective than ustekinumab for achieving clinical response and endoscopic remission.

Results presented at ACG 2023 demonstrated the viability of the HOMA-IR model for calculating insulin resistance to identify lean NAFLD.

New PUNCH CD3 analyses show patients who were treated with live fecal microbiota therapy improved their gut health at 8 weeks—which correlated with improved quality-of-life scores.

Feuerstadt reviews ACG 2023 data showing live microbiota therapy provides consistent protection against rCDI in one of the most vulnerable patient populations.

The UCLA hepatologist discusses the current treatment landscape, prospects for improved diagnostics, and the overlap syndrome live from ACG 2023.

A multi-target stool RNA test effectively screened individuals age 45 and older for colorectal cancer and advanced adenomas.

The investigator discusses the unique interplay between conditions like IBD and gestational risks—and how specialists need to improve communication.

No catch-all drug works to treat irritable bowel syndrome with constipation. But as the Mayo Clinic expert explains, enough unique options exist to tailor care better than ever.

Induction treatment with guselkumab resulted in a rapid onset of efficacy, beginning at week 1 and increasing over time to week 12, for patients with refractory moderately to severely active ulcerative colitis.

Etrasimod demonstrated rapid and significant symptomatic improvement, with differences compared to placebo evident as early as 2 days after initiation of treatment in patients with ulcerative colitis.

Study author Uma Mahadevan, MD, discusses her team's findings suggesting the concern of IBD flare risk in pregnant women receiving aspirin to prevent preeclampsia is unwarranted.

Completion of prescription app-based cognitive behavioral therapy using Mahana IBS significantly reduced symptom severity and perceived stress for patients with irritable bowel syndrome.